MAPK8 and breast carcinoma: For example, D‐JNKI‐1 (XG‐102, currently in phase III clinical trials) can inhibit JNK in breast cancer cell line model, thus breaking the splicing feedback loop of MBNL1‐MAP2K7Δexon2‐JNK, leading to a reversal of the tumorigenic dedifferentiation.107